Two studies investigated ANXA2 (annexin A2) as a diagnostic biomarker, but only one of these studies reported that it was elevated in endometrial cancer cases versus controls (AUC of 0.75 was reported in a validation cohort that also included all samples from the discovery cohort) [18], whilst it was not differentially abundant in the other study [19]. This evidence concerns the gene ANXA2 and endometrial cancer.